摘要
目的观察氨磺必利和利培酮治疗精神分裂症的疗效和安全性,以便为精神分裂症患者提供更佳的治疗方案。方法选取2012年4月～2013年4月我院收治的70名精神分裂症患者作为研究资料,按随机排列表法分成氨磺必利组和利培酮组,各35例,分别予氨磺必利药物治疗和利培酮药物治疗,治疗周期均为9周,比较两组的治疗总有效率、阳性和阴性综合征评分及不良反应发生率。结果氨磺必利组的治疗总有效率为91.4%高于利培酮组的88.6%,氨磺必利组治疗后第2周末、第4周末和第9周末阴性症状评分、阳性和阴性综合征总分均低于利培酮组,且氨磺必利组不良反应中的体重增加发生率(5.7%)及内分泌改变发生率(5.7%)均明显低于利培酮组的17.1%、20.0%,差异有统计学意义(P<0.05)。结论氨磺必利和利培酮均可有效治疗精神分裂症,但是氨磺必利对精神分裂症阴性症状的改善效果比利培酮更佳,且体重增加和内分泌改变的不良反应发生率也更低。
Objective To observe the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia, in order to provide a better treatment for patients with schizophrenia. Methods Seventy patients with schizophrenia admitted to our hospital from April 2012 to April 2013 were selected and randomized to the amisulpride group and the risperidone group, with 35 cases in each group. The two groups of patients were treated with amisulpride and risperidone, respectively, with a treatment period of 9 weeks. The total effective rate of treatment, the scores of positive and negative syndromes, and the incidence of adverse reactions were compared between the two groups. Results The total effective rate of the amisulpride group was 91.4%, which was higher than the 88.6% of the risperidone group. The scores of negative symptoms and the total scores of positive and negative syndromes at the end of the 2 nd week, 4 th week and 9 th week after treatment in the amisulpride group were lower than those of the risperidone group. The incidence of weight gain in the amisulpride group was 5.7%, and the rate of endocrine change was 5.7%, which was significantly lower than the 17.1% and 20.0% in the risperidone group, the difference were statistically significant(P<0.05).Conclusion Both amisulpride and risperidone are effective in the treatment of schizophrenia, but amisulpride is better at improving the negative symptoms of schizophrenia than risperidone, and has a lower incidence of adverse effects of weight gain and endocrine changes.
引文
[1]韩勇,姜涛.氨磺必利与利培酮对精神分裂症患者血清泌乳素水平的影响[J].山东医药,2016,56(2):88-89.
[2]陈志强,周峰,陈惠萍,等.氨磺必利与利培酮治疗精神分裂症疗效和安全性的Meta分析[J].中国药师,2015,18(2):280-283.
[3]朱庆,唐小伟,丛小兵,等.氨磺必利对阴性症状为主的精神分裂症患者认知功能的影响[J].中国临床心理学杂志,2015,23(1):97-100.
[4]迟勇.氨磺必利与利培酮对女性精神分裂症患者血清催乳素的影响研究[J].中国医刊,2016,51(2):92-95.
[5]邓良华,许世欢,徐健,等.氨磺必利治疗首次发病的精神分裂症患者的随机对照研究[J].临床精神医学杂志,2016,26(4):248-250.
[6]王灿灿,刘君.氨磺必利与利培酮治疗精神分裂症疗效及不良反应分析[J].中国急救医学,2017,37(z2):89-90.
[7]陈明友.氨磺必利和利培酮治疗精神分裂症疗效对照研究[J].精神医学杂志,2015,28(2):141-143.
[8]于晓东,季加翠,林正华,等.氨磺必利与利培酮治疗伴抑郁症状的精神分裂症对照研究[J].精神医学杂志,2016,29(4):277-279.
[9]范洪峰,居丽晶,杜启峰,等.氨磺必利与利培酮治疗首发精神分裂症的疗效比较[J].中国基层医药,2017,24(14):2199-2202.
[10]黄尚岗,阮晓晶,龚俊,等.氨磺必利和利培酮对精神分裂症患者泌乳素及孕酮的影响比较[J].中国药业,2018,27(8):80-82.
[11]韩兴玲,王惠玲.氨磺必利与利培酮治疗女性精神分裂症的疗效及不良反应[J].西南国防医药,2018,28(6):531-533.
[12]马春红.氨磺必利与利培酮治疗精神分裂症对照研究[J].中国实用神经疾病杂志,2015,18(13):121-122.
[13]吕永宾.氨磺必利和利培酮治疗精神分裂症的效果和安全性[J].中外医学研究,2017,15(19):6-8.
[14]曹月梅,董伟,丛小兵,等.氨磺必利对阴性症状为主的精神分裂症患者临床疗效及社会功能影响[J].临床心身疾病杂志,2015,21(2):28-31.
[15]王哲伟,张晓阳.氨磺必利与利培酮治疗首次发病的精神分裂症患者的疗效及对糖脂代谢影响比较[J].临床合理用药杂志,2017,10(16):82-83.
